TB-500 (Thymosin Beta-4)

TB-500 is a synthetic fragment marketed as a version of thymosin beta-4, a naturally occurring protein that binds actin and regulates how cells move into damaged tissue. The parent protein has been through early human trials for specific conditions; the fragment sold as TB-500 has not been shown to work for the muscle, tendon and recovery uses it is promoted for. In Australia it is unregistered, prescription-only, and prohibited in sport at all times.

What TB-500 is

There are two different things being discussed under this heading, and separating them is the single most useful thing this page can do.

Thymosin beta-4 (Tβ4) is a real, naturally occurring protein — a 43-amino-acid chain found in high concentration in most human cells, in platelets and in wound fluid. It has a well-described biological job, and it has been produced synthetically and taken into genuine clinical trials.

TB-500 is the name used in the grey market and in compounding for a short synthetic fragment built around the part of thymosin beta-4 responsible for binding actin. It is not the full protein. Products sold under the name vary in what they contain, and the distinction between fragment and parent protein is routinely collapsed in marketing — which allows trial evidence generated on the full protein to be presented as though it applies to the fragment in the vial.

It is typically supplied as a powder for reconstitution and injection, and is most often discussed alongside BPC-157 for injury recovery — the pair is covered in our recovery-evidence explainer.

How it works

Unlike most compounds in this category, thymosin beta-4's core mechanism is genuinely well characterised — in cell biology, not in the clinic.

The target is actin. Actin is the protein that builds the internal scaffolding of a cell. It exists in two states: G-actin, free single units floating in the cytoplasm, and F-actin, long filaments assembled from those units. A cell moves by continuously assembling filaments at its leading edge and disassembling them behind — the filament network is what physically pushes the cell forward and pulls it along.

Thymosin beta-4 is the principal G-actin sequestering protein in mammalian cells. It binds free actin monomers and holds them in a reserve pool. That sounds like it would inhibit movement, and in isolation it would — but the biological point is regulation. By buffering a large pool of monomers that can be released on demand, the cell can assemble filaments rapidly and locally, exactly where it needs to push. The actin-binding site sits in a short motif within the sequence, which is why a fragment containing that motif retains some activity and why TB-500 exists at all.

Why that matters for repair. Wound healing is, at cellular level, a migration problem. Endothelial cells move to build new vessels, keratinocytes move to close a skin wound, fibroblasts move into the defect to lay down collagen, and immune cells arrive and then leave. Anything regulating how efficiently cells crawl sits upstream of all of it.

The downstream claims. From this base, the literature describes thymosin beta-4 promoting angiogenesis, downregulating inflammatory signalling, reducing scar formation in some models, and protecting cells from programmed death after injury — all in cell and animal work.

Hold two caveats. First, thymosin beta-4 normally does its actin work inside the cell; explaining exactly how an injected peptide produces these effects from outside remains an open question, with cell-surface interactions and cellular uptake both proposed. Second, and more importantly, nearly all of this describes the full protein, not the fragment marketed as TB-500.

What the human evidence actually shows

The parent protein has real early-phase human trials. The fragment does not.

Thymosin beta-4 has been trialled in specific conditions, mostly topical or ocular. Synthetic Tβ4 has been through early-phase clinical studies in dermal wound healing — including venous stasis ulcers, pressure ulcers and epidermolysis bullosa — and, most extensively, in eye disease: dry eye and neurotrophic keratopathy, where it was delivered as eye drops. Some studies reported encouraging signals on measures such as corneal healing and symptom scores; results across the programme were mixed, and no thymosin beta-4 product has achieved registration as a medicine in Australia or comparably regulated markets. These are early-stage results in narrow indications, delivered locally rather than injected systemically.

For injected TB-500 in musculoskeletal injury, there is no randomised controlled trial evidence at all. No published RCT shows that injecting the TB-500 fragment improves tendon healing, muscle repair, ligament recovery or general "recovery" in humans. The claims made for those uses are extrapolated from animal models and from trials of a different molecule in different tissues by a different route of administration. That is three degrees of separation from the claim being made.

The animal literature is genuine. Studies in rodent and other models cover dermal wounds, corneal injury, cardiac repair after infarction, and tendon and ligament healing, with reasonably consistent repair-promoting findings. As with any preclinical body of work, this establishes that the question is worth asking in humans — not that the answer is yes.

There is no established effective human dose for the fragment, and no long-term human safety data.

The honest summary: a well-understood cell-biological mechanism, an early clinical programme in the parent protein that never reached registration, and no human evidence whatsoever for the way and the reasons the compound is actually being used.

When you read a claim about "clinical trials of thymosin beta-4", check what was trialled, in what condition, and by what route. Eye drops in dry eye do not tell you what an injection does to a torn hamstring.

Regulatory status in Australia

TB-500 and thymosin beta-4 are not on the Australian Register of Therapeutic Goods. Neither has been evaluated by the TGA for quality, safety or efficacy for human use, and there is no TGA-approved Product Information — no approved indications, contraindications or interaction data.

In practice the substance is handled as prescription-only (Schedule 4). Where an Australian patient receives it, it is as a compounded preparation made by a compounding pharmacy for that individual against a prescription from a registered practitioner. That pathway is lawful, but it is not registration, and it means:

• The preparation itself has not been assessed by the TGA.
• Identity, purity, sterility and batch consistency rest entirely on the compounding pharmacy's own quality systems.
• Because "TB-500" is not a defined registered product, what a given preparation contains — full protein, fragment, or something else — depends on the source material.

Anything sold outside that pathway — offshore websites, "research use only" suppliers, informal sources — is unlawful to supply for human use and unsafe to take, with no assurance of content or sterility. The TGA has publicly flagged concerns about unapproved peptides sold online. See our explainers on peptide legality in Australia and compounded versus TGA-registered medicines.

Direct-to-consumer advertising of prescription-only medicines is restricted in Australia — a compound like this being promoted to the public with claimed benefits is not something you should be seeing.

Anti-doping status

Thymosin beta-4 and its derivatives, including TB-500, are prohibited at all times in sport under the WADA Prohibited List, in the S2 category covering peptide hormones, growth factors, related substances and mimetics — specifically under growth factors affecting tissue regeneration and vascularisation. Sport Integrity Australia confirms it is banned and not approved for human use.

This applies at every level of competition governed by an anti-doping code, not only elite sport. Detection methods for this class exist. Use is a sanctionable finding.

Who it is being studied for — and who it is not for

Research interest has been concentrated in local repair problems — corneal injury, chronic skin wounds, cardiac tissue after infarction — and in animal models of tendon and ligament healing. The popular use, injecting it to speed recovery from a training injury in an otherwise healthy adult, is not something that has been tested.

Circumstances where a careful practitioner would be especially cautious, or would decline, include pregnancy and breastfeeding, current or previous cancer, any undiagnosed lump or lesion, and an injury that has not been properly assessed.

The oncological caution deserves stating plainly. A compound whose proposed actions are promoting cell migration and new blood-vessel formation is acting on two of the processes tumours depend on to grow and spread. Some laboratory work has reported thymosin beta-4 expression in association with tumour invasiveness. There are no human data establishing that injected TB-500 causes harm here — and none establishing that it doesn't. Unresolved is the accurate word, and unresolved is a reason for caution.

There is also the ordinary clinical point: tendon and muscle injuries have well-evidenced treatments beginning with accurate diagnosis and progressing through structured loading and rehabilitation. If a peptide is proposed before anyone has established what is actually damaged, the sequence is wrong.

Risks and considerations

With minimal human data on the injected fragment, the risk profile is unknown rather than demonstrated to be low. A thin literature reporting few problems is not a robust literature reporting safety. The practical concerns:

• Product identity and quality. Because "TB-500" is not a defined registered product, what is in a given vial varies. Grey-market peptides are frequently mislabelled, degraded or contaminated.
• Injection risk. Infection, injection-site reactions, and unsafe sharps handling are real and immediate hazards, unlike the theoretical ones.
• Unknown interactions. No Product Information exists, so no one can tell you how it behaves alongside your medicines or conditions.
• The migration-and-angiogenesis question above, which remains theoretical and open.

For athletes, use is an anti-doping rule violation however the product was obtained.

Any unexpected symptom, reaction or wound that behaves oddly should go to your treating practitioner promptly.

What to ask a doctor

• What is my actual diagnosis, and how was it reached — imaging, examination, or assumption?
• What are the proven treatments for this injury, and have I genuinely worked through them?
• Is the preparation the full thymosin beta-4 protein or a fragment, and how do you know?
• Given there is no randomised trial of injected TB-500 for my problem, what is the recommendation based on?
• Which compounding pharmacy makes it, and what quality accreditation do they hold?
• What are the realistic risks for someone with my medical and family history?
• What would tell us it is working, by when, and what is the stopping rule if it is not?
• If I compete in any tested sport, what does this do to my anti-doping status?
• What does the full course cost, including consultations, imaging and follow-up?

FAQ

Is TB-500 the same as natural thymosin beta-4? Not usually. Thymosin beta-4 is a 43-amino-acid protein that occurs naturally in your cells. Most products sold as TB-500 are a short synthetic fragment built around its actin-binding region. Trial evidence generated on the full protein does not automatically transfer to the fragment.

Is it approved or proven in humans? It is not approved in Australia or comparable markets. The parent protein reached early-phase trials in narrow indications, mainly eye and skin conditions, without achieving registration. The popular injury-recovery uses of the injected fragment have not been demonstrated in humans at all.

Can athletes use it? No. Thymosin beta-4 and its derivatives, including TB-500, are prohibited at all times under WADA rules.

How is it different from BPC-157? Different molecule, different proposed mechanism. BPC-157 is discussed mainly in terms of angiogenic and growth-factor signalling; TB-500 relates to actin binding and cell migration. What they share is being marketed for recovery on the strength of animal data, and being prohibited in sport. Using unproven compounds together multiplies the unknowns, not the evidence.

If the mechanism is so well understood, why is that not enough? Because mechanism is a hypothesis about what a drug will do, not a measurement of what it does. Plenty of compounds with textbook-clean mechanisms have failed in human trials. Mechanism tells you what to test; only trials tell you what happened.

Should I look for a clinic that offers it? Start with the injury, not the compound, and remember that a practitioner willing to tell you something is unproven is worth more than one willing to sell it to you. You can check a prescriber's AHPRA registration before any consultation, and compare doctor-supervised injury and recovery clinics once you know what you are looking for.